INDEX DATA (RAPID3)

Background: Treat-to-target with intensification of therapy according to DAS28 is documented to be an effective strategy to manage rheumatoid arthritis (RA)1. However, DAS28 and CDAI require formal joint counts, which are not performed at most rheumatology visits. RAPID3, an index of only the 3 Core Data Set patient-reported outcomes (PROs), does not include a formal joint count, and is calculated on a multidimensional health assessment questionnaire (MDHAQ) in 5 seconds. Objectives: To compare changes for DAS28, CDAI, and RAPID3 from baseline to 6 months, and the proportions of patients in 4 categories for high, moderate, low activity/severity and remission at 6 months according to each index, in the GUEPARD treat-to-target clinical trial versus ESPOIR usual care cohort. Methods: Post-hoc analyses were performed on 2 databases: 65 RA patients from the GUEPARD tight control trial and 130 matched patients from the ESPOIR usual care cohort, all with baseline DAS28≥5.12. DAS28, CDAI, and RAPID3 were compared for mean changes from baseline to 6 month